



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Baker et al. Docket No: 39780-2830P1C10
Serial No: 10/006,768 Group Art Unit: 1647
Filed: December 6, 2001 Examiner: Rachel B. Kapust
For: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME

Commissioner for Patents
Washington, D.C. 20231

Considered
RBK 6/27/04

DECLARATION OF LUC DESNOYERS, Ph.D. UNDER 37 CFR 1.131

I, Luc Desnoyers, Ph.D. declare and say as follows:

1. I am scientist at the Molecular Oncology Department of Genentech, Inc., South San Francisco, CA 94080.
2. I am one of the inventors of the above-identified application.
3. I have read and understood the claims pending in this application, and I am aware that the claims have been rejected as anticipated by International Patent Application Publication No. WO 00/00610 (Lal *et al.*, publication date January 6, 2000).
4. I, along with other inventors of this application, conceived and reduced to practice the invention claimed in the above-identified application in the United States prior to January 6, 2000.
5. At the time the present invention was made I was, as still am, responsible for overseeing the testing of novel polypeptides, including the polypeptide designated PRO1412, in chondrocyte proliferation assay (Assay #111, Example 153). This assay is used to find agents that are capable of inducing chondrocyte proliferation and/or redifferentiation, and can, therefore, be used in the treatment of joint diseases using a tissue engineering approach or as promising drug candidates to repair aging or arthritic joints, for example, in which the chondrocytes have been dedifferentiated.
6. In this assay, isolated chondrocyte cells are seeded in 96 well plates with either serum-free medium (no treatment control), or serum-free medium containing the test